CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Best available careWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2519 Tigerase® and best available care Wiki 1.00
drug2938 other Wiki 0.71

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Prospective Open-label Study of the Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19

It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Tigerase® (GENERIUM JSC, Russia) with standard therapy versus standard therapy in patients with COVID-19.

NCT04459325 COVID-19 Coronavirus Disease 201 Coronavirus Disease 2019 Biological: Tigerase® and best available care Other: Best available care
MeSH:Coronavirus Infections

Primary Outcomes

Measure: The proportion of patients with mechanical ventilation

Time: Day 8

Measure: Category change on WHO Ordinal Scale for Clinical Improvement

Time: Day 8

Secondary Outcomes

Measure: The proportion of patients with mechanical ventilation

Time: Day 28

Measure: Category change on WHO Ordinal Scale for Clinical Improvement

Time: Day 28

Measure: Proportion of patients surviving 28 days after inclusion in the study

Time: Day 28

Measure: Number of days of oxygen therapy during the treatment period

Time: Day 8

Measure: Change in C-reactive protein level

Time: Days 3, 5, 8

Description: PaO2 / FiO2, FiO2 = fraction of oxygen in inhaled air,% PaO2 = partial pressure of oxygen in arterial blood, mm Hg

Measure: Change in oxygenation index

Time: Days 3, 5, 8

Description: SpO2 / FiO2, FiO2 = fraction of oxygen in inhaled air,% SpO2 = hemoglobin oxygen saturation, %

Measure: Change in SpO2/FiO2 index

Time: Days 1, 2, 3, 4, 5, 6, 7, 8

Measure: Change in ferritin level

Time: Days 3, 5, 8

Measure: Change in D-dimer level

Time: Days 3, 5, 8

Measure: Change in neutrophil-leucocyte ratio

Time: Days 3, 5, 8

Measure: Change in leucocyte-C-reactive protein ratio

Time: Days 3, 5, 8

Measure: Change in the level of relative (%) number of lymphocytes of the general blood test

Time: Days 3, 5, 8


No related HPO nodes (Using clinical trials)